Suma Krishnan - Feb 26, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Suma Krishnan
Stock symbol
KRYS
Transactions as of
Feb 26, 2023
Transactions value $
-$239,852
Form type
4
Date filed
2/28/2023, 05:41 PM
Previous filing
Jan 19, 2023
Next filing
Apr 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Tax liability -$240K -3.06K -0.18% $78.46 1.67M Feb 26, 2023 Direct F1, F2
holding KRYS Common Stock 1.74M Feb 26, 2023 By Spouse F3
holding KRYS Common Stock 90K Feb 26, 2023 By SMK Trust
holding KRYS Common Stock 50K Feb 26, 2023 By Krishnan Family Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Award $0 +30K $0.00 30K Feb 28, 2023 Common Stock 30K $81.91 Direct F5
transaction KRYS Performance Stock Units Award $0 +15K $0.00 15K Feb 28, 2023 Common Stock 15K Direct F6, F7, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents tax withholding upon the vesting of 7,100 shares of restricted stock on February 26, 2023.
F2 The closing price on February 24, 2023 of the Company's common stock on NASDAQ.
F3 Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
F4 Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
F5 The option vests in four equal annual installments beginning on February 28, 2024.
F6 Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain corporate performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement.
F7 The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award.
F8 If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025).
F9 If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire.